Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890428190> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2890428190 abstract "TPS11082 Background: Well-differentiated/dedifferentiated liposarcoma (WD/DD LPS) is a sarcoma subtype of adipocytic origin characterized by amplification of cyclin dependent kinase 4 (CDK4) and MDM2. WD/DD LPS is resistant to chemotherapy and success with CDK4 inhibitors is limited. We recently characterized the landscape of activated receptor tyrosine kinases (RTKs) and intracellular signaling pathways finding marked heterogeneity by sarcoma subtype [Patwardhan et al. Oncotarget 2016;7(4)]. In WD/DD LPS cell lines, phosphorylated (p) IGF1-R, MET and PDGFRb are strongly expressed. Selective siRNA knockdown of expression of 1 or more of these RTKs inhibited growth of WD/DD LPS cell lines. Sitravatinib (S) is a novel inhibitor of a broad panel of related RTKs. We showed that S abrogates expression of p-RTKs, including IGF1-R, MET and PDGFRb, at low nanomolar concentrations and potently inhibits proliferation of WD/DD LPS cell lines, where anti-proliferative effects of S were superior to other RTK inhibitors including imatinib, crizotinib and pazopanib. S suppressed tumor growth in vivo in WD/DD LPS . A phase 1 trial of S in solid tumors showed clinical activity in WD/DD LPS. Recommended phase 2 dose was 150 mg/day. As there are no approved RTK inhibitors for adipocytic sarcomas, and based on these findings, we initiated a phase 2 trial of S in WD/DD LPS. Methods: This is a single-arm open-label multi-center Simon 2 stage phase II trial of S in 29 patients (pts) with advanced WD/DD LPS who failed 1 prior therapy and show disease progression before enrollment. Pts receive S 150 mg orally daily continuously. Primary endpoint is the progression free rate at 12 weeks (PFR 12 ) versus historical controls. The design has power of 85% to show improvement in PFR 12 from 20% (inactive) to 40% (active) with α = 0.10. Secondary endpoints are ORR, PFS and safety. A subset of pts undergo baseline and on-treatment biopsies and reverse phase protein array used to measure changes in expression of p-RTKs and signaling pathway proteins with confirmation by immunoblot. Genomic landscape of these tumors will be analyzed by next generation sequencing. The study opened in 1/2017. Clinical trial information: NCT02978859." @default.
- W2890428190 created "2018-09-27" @default.
- W2890428190 creator A5006913373 @default.
- W2890428190 creator A5006994766 @default.
- W2890428190 creator A5007697804 @default.
- W2890428190 creator A5017491012 @default.
- W2890428190 creator A5031842757 @default.
- W2890428190 creator A5034055406 @default.
- W2890428190 creator A5063926652 @default.
- W2890428190 creator A5071532449 @default.
- W2890428190 date "2017-05-20" @default.
- W2890428190 modified "2023-09-28" @default.
- W2890428190 title "Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma." @default.
- W2890428190 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps11082" @default.
- W2890428190 hasPublicationYear "2017" @default.
- W2890428190 type Work @default.
- W2890428190 sameAs 2890428190 @default.
- W2890428190 citedByCount "1" @default.
- W2890428190 countsByYear W28904281902019 @default.
- W2890428190 crossrefType "journal-article" @default.
- W2890428190 hasAuthorship W2890428190A5006913373 @default.
- W2890428190 hasAuthorship W2890428190A5006994766 @default.
- W2890428190 hasAuthorship W2890428190A5007697804 @default.
- W2890428190 hasAuthorship W2890428190A5017491012 @default.
- W2890428190 hasAuthorship W2890428190A5031842757 @default.
- W2890428190 hasAuthorship W2890428190A5034055406 @default.
- W2890428190 hasAuthorship W2890428190A5063926652 @default.
- W2890428190 hasAuthorship W2890428190A5071532449 @default.
- W2890428190 hasConcept C101544691 @default.
- W2890428190 hasConcept C121608353 @default.
- W2890428190 hasConcept C126322002 @default.
- W2890428190 hasConcept C143998085 @default.
- W2890428190 hasConcept C170493617 @default.
- W2890428190 hasConcept C184235292 @default.
- W2890428190 hasConcept C2778820342 @default.
- W2890428190 hasConcept C42362537 @default.
- W2890428190 hasConcept C502942594 @default.
- W2890428190 hasConcept C71924100 @default.
- W2890428190 hasConcept C86803240 @default.
- W2890428190 hasConcept C95444343 @default.
- W2890428190 hasConceptScore W2890428190C101544691 @default.
- W2890428190 hasConceptScore W2890428190C121608353 @default.
- W2890428190 hasConceptScore W2890428190C126322002 @default.
- W2890428190 hasConceptScore W2890428190C143998085 @default.
- W2890428190 hasConceptScore W2890428190C170493617 @default.
- W2890428190 hasConceptScore W2890428190C184235292 @default.
- W2890428190 hasConceptScore W2890428190C2778820342 @default.
- W2890428190 hasConceptScore W2890428190C42362537 @default.
- W2890428190 hasConceptScore W2890428190C502942594 @default.
- W2890428190 hasConceptScore W2890428190C71924100 @default.
- W2890428190 hasConceptScore W2890428190C86803240 @default.
- W2890428190 hasConceptScore W2890428190C95444343 @default.
- W2890428190 hasLocation W28904281901 @default.
- W2890428190 hasOpenAccess W2890428190 @default.
- W2890428190 hasPrimaryLocation W28904281901 @default.
- W2890428190 hasRelatedWork W1008777709 @default.
- W2890428190 hasRelatedWork W150724498 @default.
- W2890428190 hasRelatedWork W1560827802 @default.
- W2890428190 hasRelatedWork W1581028528 @default.
- W2890428190 hasRelatedWork W1604533136 @default.
- W2890428190 hasRelatedWork W1994438989 @default.
- W2890428190 hasRelatedWork W1994487360 @default.
- W2890428190 hasRelatedWork W2018910306 @default.
- W2890428190 hasRelatedWork W2086478259 @default.
- W2890428190 hasRelatedWork W2086718822 @default.
- W2890428190 hasRelatedWork W2091816733 @default.
- W2890428190 hasRelatedWork W2111631361 @default.
- W2890428190 hasRelatedWork W2145147997 @default.
- W2890428190 hasRelatedWork W2148996258 @default.
- W2890428190 hasRelatedWork W2267202447 @default.
- W2890428190 hasRelatedWork W2894408895 @default.
- W2890428190 hasRelatedWork W2896657170 @default.
- W2890428190 hasRelatedWork W2995627342 @default.
- W2890428190 hasRelatedWork W3044592137 @default.
- W2890428190 hasRelatedWork W3045016484 @default.
- W2890428190 isParatext "false" @default.
- W2890428190 isRetracted "false" @default.
- W2890428190 magId "2890428190" @default.
- W2890428190 workType "article" @default.